Mara Rabin, MD
Family Medicine · Salt Lake City, UTNPI 1225161003
Payments from drug & device makers
Across 189 payments — averaging $5670.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$249K
- Organon$225K
- Mylan Inc.$157K
- Sumitomo Pharma America, Inc.$129K
- Mylan Technologies Inc.$125K
- Eli Lilly$68K
- plus $118K from 14 others
Across 1 payment — averaging $14,341 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$14K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 11 | $249,009 |
| Organon | 44 | $224,663 |
| Mylan Inc. | 26 | $157,302 |
| Sumitomo Pharma America, Inc. | 47 | $129,409 |
| Mylan Technologies Inc. | 8 | $125,478 |
| Eli Lilly | 8 | $68,081 |
| Biohaven Pharmaceuticals, Inc. | 9 | $53,600 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $35,055 |
| Myovant Sciences GmbH | 9 | $18,760 |
| Myovant Sciences Inc. | 3 | $8,118 |
| Lexicon Pharmaceuticals, Inc. | 1 | $1,800 |
| AbbVie | 9 | $209 |
| Dexcom, Inc. | 2 | $41 |
| Exact Sciences | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Boston Scientific | 1 | $16 |
| GSK | 1 | $15 |
How this compares
$1,071,649 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Salt Lake City
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Sarang YoonSalt Lake City$9.4M
- Stephen ColemanSalt Lake City$2M
- Albert JarviSalt Lake City$1.6M
- Derek MuseSalt Lake City$1.3M
- David LarsenSalt Lake City$1.2M
- John WitbeckSalt Lake City$235K
- Mark JohnsonSalt Lake City$114K
- Mark CacciamaniSalt Lake City$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.